Thomas Uray1, Philip E Empey2, Tomas Drabek3, Jason P Stezoski4, Keri Janesko-Feldman5, Travis Jackson4, Robert H Garman6, Francis Kim7, Patrick M Kochanek4, Cameron Dezfulian8. 1. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, PA, USA; Department of Critical Care Medicine, University of Pittsburgh School of Medicine, PA, USA; Department of Emergency Medicine, Medical University of Vienna, Austria. 2. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, PA, USA; Department of Pharmacy and Therapeutics, University of Pittsburgh, PA, USA. 3. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, PA, USA; Department of Anesthesiology, University of Pittsburgh School of Medicine, PA, USA. 4. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, PA, USA; Department of Critical Care Medicine, University of Pittsburgh School of Medicine, PA, USA. 5. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, PA, USA. 6. Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA. 7. Department of Medicine, Harborview Medical Center, University of Washington, Seattle, WA, USA. 8. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, PA, USA; Department of Critical Care Medicine, University of Pittsburgh School of Medicine, PA, USA; Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: dezfulianc@upmc.edu.
Abstract
INTRODUCTION: Besides therapeutic hypothermia or targeted temperature management no novel therapies have been developed to improve outcomes of patients after cardiac arrest (CA). Recent studies suggest that nitrite reduces neurological damage after asphyxial CA. Nitrite is also implicated as a new mediator of remote post conditioning produced by tourniquet inflation-deflation, which is under active investigation in CA. However, little is known about brain penetration or pharmacokinetics (PK). Therefore, to define the optimal use of this agent, studies on the PK of nitrite in experimental ventricular fibrillation (VF) are needed. We tested the hypothesis that nitrite administered after resuscitation from VF is detectable in cerebrospinal fluid (CSF), brain and other organ tissues, produces no adverse hemodynamic effects, and improves neurologic outcome in rats. METHODS:After return of spontaneous circulation (ROSC) of 5 min untreated VF, adult male Sprague-Dawley rats were given intravenous nitrite (8 μM, 0.13 mg/kg) or placebo as a 5 min infusion beginning at 5 min after CA. Additionally, sham groups with and without nitrite treatment were also studied. Whole blood nitrite levels were serially measured. After 15 min, CSF, brain, heart and liver tissue were collected. In a second series, using a randomized and blinded treatment protocol, rats were treated with nitrite or placebo after arrest. Neurological deficit scoring (NDS) was performed daily and eight days after resuscitation, fear conditioning testing (FCT) and brain histology were assessed. RESULTS: In an initial series of experiments, rats (n = 21) were randomized to 4 groups: VF-CPR and nitrite therapy (n = 6), VF-CPR and placebo therapy (n = 5), sham (n = 5), or sham plus nitrite therapy (n = 5). Whole blood nitrite levels increased during drug infusion to 57.14 ± 10.82 μM at 11 min post-resuscitation time (1 min after dose completion) in the VF nitrite group vs. 0.94 ± 0.58 μM in the VF placebo group (p < 0.001). There was a significant difference between the treatment and placebo groups in nitrite levels in blood between 7.5 and 15 min after CPR start and between groups with respect to nitrite levels in CSF, brain, heart and liver. In a second series (n = 25 including 5 shams), 19 out of 20 animals survived until day 8. However, NDS, FCT and brain histology did not show any statistically significant difference between groups. CONCLUSIONS: Nitrite, administered early after ROSC from VF, was shown to cross the blood brain barrier after a 5 min VF cardiac arrest. We characterized the PK of intravenous nitrite administration after VF and were able to demonstrate nitrite safety in this feasibility study.
RCT Entities:
INTRODUCTION: Besides therapeutic hypothermia or targeted temperature management no novel therapies have been developed to improve outcomes of patients after cardiac arrest (CA). Recent studies suggest that nitrite reduces neurological damage after asphyxial CA. Nitrite is also implicated as a new mediator of remote post conditioning produced by tourniquet inflation-deflation, which is under active investigation in CA. However, little is known about brain penetration or pharmacokinetics (PK). Therefore, to define the optimal use of this agent, studies on the PK of nitrite in experimental ventricular fibrillation (VF) are needed. We tested the hypothesis that nitrite administered after resuscitation from VF is detectable in cerebrospinal fluid (CSF), brain and other organ tissues, produces no adverse hemodynamic effects, and improves neurologic outcome in rats. METHODS: After return of spontaneous circulation (ROSC) of 5 min untreated VF, adult male Sprague-Dawley rats were given intravenous nitrite (8 μM, 0.13 mg/kg) or placebo as a 5 min infusion beginning at 5 min after CA. Additionally, sham groups with and without nitrite treatment were also studied. Whole blood nitrite levels were serially measured. After 15 min, CSF, brain, heart and liver tissue were collected. In a second series, using a randomized and blinded treatment protocol, rats were treated with nitrite or placebo after arrest. Neurological deficit scoring (NDS) was performed daily and eight days after resuscitation, fear conditioning testing (FCT) and brain histology were assessed. RESULTS: In an initial series of experiments, rats (n = 21) were randomized to 4 groups: VF-CPR and nitrite therapy (n = 6), VF-CPR and placebo therapy (n = 5), sham (n = 5), or sham plus nitrite therapy (n = 5). Whole blood nitrite levels increased during drug infusion to 57.14 ± 10.82 μM at 11 min post-resuscitation time (1 min after dose completion) in the VFnitrite group vs. 0.94 ± 0.58 μM in the VF placebo group (p < 0.001). There was a significant difference between the treatment and placebo groups in nitrite levels in blood between 7.5 and 15 min after CPR start and between groups with respect to nitrite levels in CSF, brain, heart and liver. In a second series (n = 25 including 5 shams), 19 out of 20 animals survived until day 8. However, NDS, FCT and brain histology did not show any statistically significant difference between groups. CONCLUSIONS:Nitrite, administered early after ROSC from VF, was shown to cross the blood brain barrier after a 5 min VF cardiac arrest. We characterized the PK of intravenous nitrite administration after VF and were able to demonstrate nitrite safety in this feasibility study.
Authors: Matilde Winther-Jensen; Tommaso Pellis; Michael Kuiper; Matty Koopmans; Christian Hassager; Niklas Nielsen; Jørn Wetterslev; Tobias Cronberg; David Erlinge; Hans Friberg; Yvan Gasche; Janneke Horn; Jan Hovdenes; Pascal Stammet; Michael Wanscher; Matthew P Wise; Anders Åneman; Jesper Kjaergaard Journal: Resuscitation Date: 2015-01-15 Impact factor: 5.262
Authors: Cameron Dezfulian; Michele Olsufka; Deborah Fly; Sue Scruggs; Rose Do; Charles Maynard; Graham Nichol; Francis Kim Journal: Resuscitation Date: 2017-11-23 Impact factor: 5.262
Authors: Zhi Huang; Sruti Shiva; Daniel B Kim-Shapiro; Rakesh P Patel; Lorna A Ringwood; Cynthia E Irby; Kris T Huang; Chien Ho; Neil Hogg; Alan N Schechter; Mark T Gladwin Journal: J Clin Invest Date: 2005-07-21 Impact factor: 14.808
Authors: Gisela Lilja; Niklas Nielsen; Hans Friberg; Janneke Horn; Jesper Kjaergaard; Fredrik Nilsson; Tommaso Pellis; Jørn Wetterslev; Matt P Wise; Frank Bosch; John Bro-Jeppesen; Iole Brunetti; Azul Forti Buratti; Christian Hassager; Caisa Hofgren; Angelo Insorsi; Michael Kuiper; Alice Martini; Nicki Palmer; Malin Rundgren; Christian Rylander; Annelou van der Veen; Michael Wanscher; Helen Watkins; Tobias Cronberg Journal: Circulation Date: 2015-02-13 Impact factor: 29.690
Authors: Cameron Dezfulian; Sruti Shiva; Aleksey Alekseyenko; Akshay Pendyal; D G Beiser; Jeeva P Munasinghe; Stasia A Anderson; Christopher F Chesley; T L Vanden Hoek; Mark T Gladwin Journal: Circulation Date: 2009-08-24 Impact factor: 29.690
Authors: Cameron Dezfulian; Elizabeth Kenny; Andrew Lamade; Amalea Misse; Nicholas Krehel; Claudette St Croix; Eric E Kelley; Travis C Jackson; Thomas Uray; Justin Rackley; Patrick M Kochanek; Robert S B Clark; Hulya Bayir Journal: J Neurochem Date: 2016-10-03 Impact factor: 5.372
Authors: Francis Kim; Cameron Dezfulian; Philip E Empey; Matthew Morrell; Michele Olsufka; Sue Scruggs; Peter Kudenchuk; Susanne May; Charles Maynard; Michael R Sayre; Graham Nichol Journal: Am J Cardiol Date: 2018-06-20 Impact factor: 2.778
Authors: Julian O M Ormerod; Sayqa Arif; Majid Mukadam; Jonathan D W Evans; Roger Beadle; Bernadette O Fernandez; Robert S Bonser; Martin Feelisch; Melanie Madhani; Michael P Frenneaux Journal: Circ Heart Fail Date: 2015-04-02 Impact factor: 8.790